Loxenatide
Sources
registry, as of 2026-03-13Stale
https://clinicaltrials.gov/study/NCT05172999
Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia. Overall status COMPLETED. Phases PHASE2,PHASE3. Lead sponsor Fudan University. Enrollment 30. Conditions Atypical Endometrial Hyperplasia; Obesity; Fertility Issues. To study if polyethylene glycol loxenatide plus levonorgestrel-releasing intrauterine system (LNG-IUS) will improve response rates in patients with endometrial atypical hyperplasia.
ClinicalTrials.gov NCT05172999 protocol and results modules